New combo aims to reboot immune attack in stubborn cancers

NCT ID NCT06270706

Recruiting now Disease control Sponsor: Pliant Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 23, 2026 · Last updated May 21, 2026 · Updated 3 times

Summary

This early-phase study tests an experimental drug (PLN-101095) alone or with the immunotherapy pembrolizumab in about 124 adults whose advanced solid tumors grew despite prior pembrolizumab treatment. The main goals are to check safety and find the right dose, while also looking for signs that the combination can shrink tumors or stop them from growing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

NEXT Austin
RECRUITING

Austin, Texas, 78758, United States

Contact Email: •••••@•••••
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States

Contact Email: •••••@•••••
South Texas Accelerated Research Therapeutics (START)
RECRUITING

Grand Rapids, Michigan, 49546, United States

Contact Email: •••••@•••••
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Email: •••••@•••••
Winship Cancer Institute of Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

Contact Email: •••••@•••••
Yale University
ACTIVE_NOT_RECRUITING

New Haven, Connecticut, 06511, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED OR METASTATIC SOLID TUMOR